Work

Anti-amyloid therapies in the Brazilian public health system: challenges and barriers

Year: 2025

Type: article

Abstract: The recent approval of donanemab by Brazil's National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária - Anvisa) in 20251 was met with enthusiasm by much of the medical community and by families of individuals living with Alzheimer's disease (AD). It was based on the results of a clinical trial that showed statistically significant differences in the rate of cognitive decline among individuals with early-stage AD.2 However, the results did not reach the minimum clinically important difference (MCID).

Source: The Lancet Regional Health - Americas

DOI: 10.1016/j.lana.2025.101224

Authors: Raphael Machado Castilhos, Elisa Resende, Adalberto Studart Neto

Institutions: Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Universidade Federal de Minas Gerais, Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,930